Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
NCT ID: NCT05501665
Last Updated: 2024-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
25 participants
INTERVENTIONAL
2023-05-09
2027-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
NCT03663166
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT04929041
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01711697
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT05096663
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Evaluate the safety of adaptive split course hypo-fractionated radiation therapy (RT) with immunotherapy containing systemic regimens.
II. Evaluate efficacy of the use of adaptive split course hypo-fractionated RT with immunotherapy containing systemic regimens.
SECONDARY OBJECTIVES:
I. Evaluate progression and survival benefit of split course adaptive radioimmunotherapy (SiCARIO) regimen.
II. Identify potential functional radiomic biomarkers of response to SiCARIO regimen.
III. Develop real-world clinical and treatment planning workflows for implementation of the Ethos platform for anatomic and biologically adaptive RT.
OUTLINE:
PRIMARY OBJECTIVES:
I. Evaluate the safety of adaptive split course hypo-fractionated radiation therapy (RT) with immunotherapy containing systemic regimens.
II. Evaluate efficacy of the use of adaptive split course hypo-fractionated RT with immunotherapy containing systemic regimens.
SECONDARY OBJECTIVES:
I. Evaluate progression and survival benefit of split course adaptive radioimmunotherapy (SiCARIO) regimen.
II. Identify potential functional radiomic biomarkers of response to SiCARIO regimen.
III. Develop real-world clinical and treatment planning workflows for implementation of the Ethos platform for anatomic and biologically adaptive RT.
OUTLINE:
Patients are assigned to 1 of 11 standard treatment regimens, in combination with radiation therapy, as determined by the tumor histology and PD-L1 status.
Patients with non-squamous histology and any PD-L1 status are assigned to arms 1-4.
ARM I: Patients receive carboplatin, pemetrexed, and pembrolizumab on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pemetrexed and pembrolizumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
ARM II: Patients receive carboplatin, pemetrexed and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pemetrexed and cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
ARM III: Patients receive carboplatin, paclitaxel and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pemetrexed and cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
ARM IV: Patients receive carboplatin, pemetrexed and nivolumab on day 1 of each cycle and ipilimumab on day 1 of every other cycle. Treatment repeats for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive ipilmumab and nivolumab on the same schedule for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
Patients with squamous histology and any PD-L1 histology are assigned to arms 5-7
ARM V: Patients receive carboplatin, paclitaxel, and pembrolizumab on day 1 of each cycle. Treatment repeats every 3 weeks for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. Patients then receive pembrolizumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
ARM VI: Patients receive carboplatin, paclitaxel, and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. Patients then receive cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
ARM VII: Patients receive carboplatin, paclitaxel and nivolumab on day 1 of each cycle and ipilimumab on day 1 of every other cycle. Treatment repeats for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive ipilmumab and nivolumab on the same schedule for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
Patients with PD-L1 ≥ 50% are assigned to arms 8-10
ARM VIII: Patients receive pembrolizumab on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
ARM IX: Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
ARM X: Patients receive cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
Patients with any PD-L1 status or histology who are not a chemotherapy candidate are assigned to arm 11
ARM XI: Patients receive ipilmumab every 6 weeks and nivolumab every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
After completion of study treatment, patients are followed up at 4 weeks, 12 weeks, and then every 12 weeks for 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 (carboplatin, pemetrexed, pembrolizumab, radiation)
Patients receive carboplatin, pemetrexed, and pembrolizumab on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pemetrexed and pembrolizumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Carboplatin
Given carboplatin
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Pembrolizumab
Given pembrolizumab
Pemetrexed
Given pemetrexed
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Arm II (carboplatin, pemetrexed, cemiplimab, radiation)
Patients receive carboplatin, pemetrexed and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pemetrexed and cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Carboplatin
Given carboplatin
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Pemetrexed
Given pemetrexed
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Cemiplimab
Given Cemiplimab
Arm III (carboplatin, paclitaxel, cemiplimab-rwlc, radiation)
Patients receive carboplatin, paclitaxel and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pemetrexed and cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Carboplatin
Given carboplatin
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Nab-paclitaxel
Given nab-paclitaxel
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Cemiplimab
Given Cemiplimab
Arm IV (Carbo, pemetrexed, nivolumab, ipilimumab, radiation)
Patients receive carboplatin, pemetrexed and nivolumab on day 1 of each cycle and ipilimumab on day 1 of every other cycle. Treatment repeats for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive ipilmumab and nivolumab on the same schedule for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Carboplatin
Given carboplatin
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Pemetrexed
Given pemetrexed
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Ipilimumab
Given Ipilimumab
Nivolumab
Given Nivolumab
Arm V (Carboplatin, paclitaxel, pembrolizumab, radiation)
Patients receive carboplatin, paclitaxel, and pembrolizumab on day 1 of each cycle. Treatment repeats every 3 weeks for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. Patients then receive pembrolizumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Carboplatin
Given carboplatin
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Nab-paclitaxel
Given nab-paclitaxel
Pembrolizumab
Given pembrolizumab
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Arm VI (Carboplatin, paclitaxel, cemiplimab-rwlc, radiation)
Patients receive carboplatin, paclitaxel, and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. Patients then receive cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Carboplatin
Given carboplatin
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Nab-paclitaxel
Given nab-paclitaxel
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Cemiplimab
Given Cemiplimab
Arm VII (carbo, paclitaxel, nivolumab, ipilimumab, radiation)
Patients receive carboplatin, paclitaxel, and cemiplimab-rwlc on day 1 of each cycle. Treatment repeats every 3 weeks for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. Patients then receive cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Carboplatin
Given carboplatin
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Nab-paclitaxel
Given nab-paclitaxel
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Ipilimumab
Given Ipilimumab
Nivolumab
Given Nivolumab
Arm VIII (pembrolizumab, radiation)
Patients receive pembrolizumab on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Pembrolizumab
Given pembrolizumab
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Arm IX (atezolizumab, radiation)
Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Atezolizumab
Given Atezolizumab
Arm X (cemiplimab-rwlc, radiation)
Patients receive cemiplimab-rwlc on day 1 of each cycle. Cycles repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Cemiplimab
Given Cemiplimab
Arm XI (nivolumab, ipilumumab, radiation)
Patients receive ipilmumab every 6 weeks and nivolumab every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions. All patients also receive fludeoxyglucose F-18 intravenously and fluorine F 18 florilglutamic acid IV and undergo PET/ CT during screening and on study. Patients also undergo collection of blood samples, as well as CT and MRI throughout the trial.
Biospecimen Collection
Correlative studies
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Ipilimumab
Given Ipilimumab
Nivolumab
Given Nivolumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biospecimen Collection
Correlative studies
Carboplatin
Given carboplatin
Computed Tomography
Undergo PET/CT
Fludeoxyglucose F-18
Given IV
Nab-paclitaxel
Given nab-paclitaxel
Pembrolizumab
Given pembrolizumab
Pemetrexed
Given pemetrexed
Positron Emission Tomography
Undergo PET/CT
Radiation Therapy
Undergo radiation therapy
[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Undergo PET scan
Ipilimumab
Given Ipilimumab
Nivolumab
Given Nivolumab
Cemiplimab
Given Cemiplimab
Atezolizumab
Given Atezolizumab
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* • Histologically documented or cytologically confirmed diagnosis of stage IVA or IVB (M1b or M1c) or locally advanced (not eligible for standard of care \[SOC\] chemoradiation) non-small cell lung cancer with evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria
* Available tumor material (\< 6 months old) adequate for confirmation of programmed cell death 1 ligand 1 (PD-L1) expression per local standard of care testing
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Adequate organ function to receive therapy as determined by investigators and other treating physicians
* Participants with brain metastases that can be comprehensively managed with surgery and/or stereotactic radiosurgery, prior to initiation of chemo-immunotherapy are allowed. Number of brain metastases allowed is not specified at eligibility is at discretion of investigator
* Contraceptive use should be initiated or continued per guidance in labeling for approved chemotherapies
* Female patients must be non-pregnant and not breastfeeding.
* If woman of childbearing potential (WOCBP), must utilize highly effective contraceptive method (failure rate of \< 1% per year) throughout intervention period and continued per guidance specified in labeling for approved chemotherapies. Must have negative pregnancy test (serum or urine) within 1 week prior to initiation of first cycle of therapy
* Eligible for immunotherapy-based systemic regimens per judgment of patient's study physician
* Able to submit written informed consent
Exclusion Criteria
* Confirmed candidate (per study physician) for alternative systemic therapy if preferred by treating physician (i.e. mEGFR, ALK, KRAS G12C or ROS1 mutations). Testing not required for enrollment
* Brain metastases that would require administration of whole brain radiotherapy for management on required screening brain MRI within 21 days of day 1 of study treatment
* Symptomatic malignant ascites or malignant pleural effusion (sampling not required). Pleural metastases are allowed if deemed targetable with radiotherapy
* Major surgery (requiring general anesthesia or at discretion of study physician) within 4 weeks prior to study enrollment that would prevent treatment with SiCARIO regimen
* History of organ transplant requiring therapeutic immunosuppression
* Known clinically significant (per study physician) acute or chronic infections including human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis (testing not required). Patients with HBV and HCV must be on stable dose of antiviral therapy on study entry
* Uncontrolled intercurrent illness including, but not limited to, New York Heart Association (NYHA) class III-IV congestive heart failure, uncontrolled hypertension (average systolic blood pressure greater than or equal to 140 or average diastolic blood pressure greater than or equal to 90 despite optimal medical therapy), unstable angina pectoris, cardiac arrythmia, active peptic ulcer disease, bleeding diatheses or psychiatric illness that would limit in the judgment of the study physician
* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 30 days of day 1 of study treatment
* History of prior independent malignancy within 3 years of enrollment, except for adequately treated basal or squamous cell carcinoma of the skin, adequately treated carcinoma in situ (e.g. cervix or non-invasive bladder cancer)
* Receipt of prior \>1 cycle of immune checkpoint inhibitor for current malignancy (prior cytotoxic chemotherapy is allowed)
* Prior radiotherapy that would preclude delivery of protocol- based radiotherapy to normal organ tolerance per patient's study physician
* Current or prior use of immunosuppressive medications within 28 days of enrollment with exception of intranasal or inhaled corticosteroids or systemic steroids at physiologic doses (equivalent to less than or equal to 10 mg/day of prednisone). Systemic steroids required during therapy for adverse event (AE) management and for residual neurologic complications from management of central nervous system (CNS) metastases are allowed at doses exceeding 10 mg/day of prednisone equivalents
* Active autoimmune disease requiring systemic treatment within past 1 year
* Receipt of live attenuated vaccine within 30 days of enrollment
* Use of prohibited concomitant drug within 30 days of enrollment
* Known severe (\>= grade 3 Common Terminology Criteria for Adverse Events \[CTCAE\]) hypersensitivity to study intervention or formulation
* Concurrent enrollment in another clinical trial (unless observational or within follow-up period)
* Any condition at discretion of investigator that will preclude participation in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Varian Medical Systems
INDUSTRY
Vanderbilt-Ingram Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Evan Osmundson, MD, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Evan Osmundson, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt University/Ingram Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2022-05101
Identifier Type: REGISTRY
Identifier Source: secondary_id
VICCTHOP2185
Identifier Type: OTHER
Identifier Source: secondary_id
VICCTHOP2185
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.